HepaTx Develops Effective Alternative

A real estate investment professional with more than three decades of experience in affordable housing, Gil Seton serves as a manager of SP Investment Fund, LLC, a Los Angeles, California-based investment firm. As the manager of the firm, Gil Seton oversees the investments of SP and its affiliates in affordable housing developments and emerging technology and biotechnology startups that will benefit society, such as HepaTx.

A regenerative medicine technology pioneer, HepaTx is working on a cutting-edge therapy for liver diseases that rely on stem cells. With this therapy, patients with late-stage liver disease can avoid liver transplants. In the United States, over 30 million individuals are diagnosed with liver disease and live less comfortably. Each year, about 7 percent of the affected population develop end-stage liver failure, which necessitates transplant for the patients' survival.

A liver transplant is not available to all patients. Approximately, only 3 percent of patients in need of the surgery have access to the treatment. As this is a matter of life and death, finding promising alternatives is critical. HepaTx's solution replaces the lost regenerative capacity of a defective liver. With this, the liver may recover its vitality and become a healthy organ again.